Samrat Pharmachem Limited

BSE: 530125
Samrat Pharmachem Limited - chemicals and materials in Ankleshwar, Gujarat, India. FY 2026 financials and compliance.
CIN L24230GJ1992PLC017820 Incorporated 16 June 1992 ROC Ahmedabad HQ Ankleshwar, Gujarat, India
Active Listed - BSE: 530125 Public Limited Company chemicals and materials
Data last updated
Revenue · FY 2026
₹289.72 Cr
▲ 1.35% YoY
EBITDA · FY 2026
-₹1.31 Cr
▼ 111.64% YoY
Net profit · FY 2026
-₹3.31 Cr
▼ 146.57% YoY
Authorised capital
₹5 Cr
Registered with MCA
Paid-up capital
₹3.09 Cr
Issued & subscribed
Open charges
₹69 Cr
Satisfied ₹17.55 Cr
Company age
34 yrs
Est. 1992
Employees · EPFO
26
Latest available

About Samrat Pharmachem Limited

Data last updated: 09 January 2026

Samrat Pharmachem Limited is a public limited company based in Ankleshwar, Gujarat, India. It specialises in specialty chemicals, a part of the broader chemicals and materials sector. Incorporated on 16 June 1992, the company has been in operation for over 34 years.

Registered with ROC Ahmedabad under CIN L24230GJ1992PLC017820. Listed on BSE: 530125.

Capital: an authorised share capital of ₹5 Cr and a paid-up capital of ₹3.09 Cr. It is led by directors including Renu Piyush Dharod and Megh Rajesh Mehta.

Last AGM: 25 September 2025. Financial statements filed for year ended 31 March 2025. Office: Ankleshwar, Gujarat.

As per the financials filed for FY 2025, the company reported a revenue of ₹286.83 Cr, a growth of 1% compared to the previous year.

The company has a workforce of approximately 26 employees as per the latest available data.

The company is associated with 1 brand - Samrat Pharmachem. As per MCA filings, the company has open charges of ₹69 Cr and satisfied charges of ₹17.55 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website samratpharmachem.com.

Company Details of Samrat Pharmachem Limited
CIN L24230GJ1992PLC017820
Registration Number 017820
Incorporation Date 16 June 1992
ROC Ahmedabad
Listing Status Listed (BSE: 530125)
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Lalit Damodar Mehta Managing Director Renu Piyush Dharod Director Megh Rajesh Mehta Deputy Nodal Officer
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    samratpharmachem.com
  • Social Media
  • Registered Address
    Plot No. A2 – 3444 – 3445, Gidc Phase 4, Ankleshwar, Gujarat, India – 393002
  • Industry
    Chemicals and Materials, Specialty Chemicals
Company report
Samrat Pharmachem Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Samrat Pharmachem Limited report

Financials, compliance, directors, charges, ownership and filings for Samrat Pharmachem Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Samrat Pharmachem Limited

Samrat Pharmachem Limited has one previous CIN (Corporate Identification Number): U24230GJ1992PLC017820. The current CIN is L24230GJ1992PLC017820, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24230GJ1992PLC017820 Current
U24230GJ1992PLC017820 Previous

Associated Brands with Samrat Pharmachem Limited

Samrat Pharmachem Limited operates one associated brand: Samrat Pharmachem. These brands represent Samrat Pharmachem Limited's diversified market presence and brand portfolio.

Brand Description Website
Samrat Pharmachem
Chemicals are manufactured for pharma, food, and fertilizer industries. samratpharmachem.com

Competitors & Alternatives of Samrat Pharmachem Limited

Brands and companies operating in the same space as Samrat Pharmachem Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.

Competitor Description Location Founded
Laurus Labs Laurus Labs Pharmaceutical and biotechnology company Hyderabad, India, India 2005
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured. Indore, India, India 2002
Beijing Biostar Technologies Beijing Biostar Technologies APIs, intermediates, and biochemical reagents are developed and manufactured. Beijing, China, China 2002
Sterling Pharma Solutions Sterling Pharma Solutions Contract development, manufacturing, and analytical services for APIs are offered. Dudley, United Kingdom, United Kingdom 2016
Provepharm Life Solutions Provepharm Life Solutions APIs and drug products are developed and valorized in pharmaceuticals. Marseille, France, France 1998
Hikal Hikal APIs and intermediates are produced via custom synthesis and research. Mumbai, India, India 1988
Snapdragon Chemistry Snapdragon Chemistry Drug discovery and development service provider Cambridge, United States, United States 2014
SeQuent SeQuent APIs are developed and manufactured for therapeutic areas. Bengaluru, India, India 2002
Jubilant Pharma Jubilant Pharma Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. Noida, India, India 1978

Business Activity of Samrat Pharmachem Limited

Samrat Pharmachem Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Samrat Pharmachem Limited

Samrat Pharmachem Limited is audited by Shah & Savla LLP (ICAI peer reviewed, certificate valid till 2027-04-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Shah & Savla LLP (ICAI peer reviewed, certificate valid till 2027-04-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Samrat Pharmachem Limited

Samrat Pharmachem Limited is currently managed by 9 directors, with 10 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Renu Piyush Dharod Director 14 Feb 2015 11 Years 4 Months Current
Megh Rajesh Mehta Deputy Nodal Officer 18 Dec 2023 2 Years 6 Months Current
Manishkumar Indukumar Pipalia Director 23 Jul 2024 1 Years 11 Months Current
Rajesh Lalit Mehta Nodal Officer 18 Dec 2023 2 Years 6 Months Current
Lalit Damodar Mehta Managing Director 16 Jun 1992 34 Years 0 Months Current
Sachin Samir Kothary Director 23 Jul 2024 1 Years 11 Months Current
Showing 6 of 9 current directors. View all directors

Financials of Samrat Pharmachem Limited FY 2026 filings available

Samrat Pharmachem Limited reported revenue of ₹289.72 Cr (up 1.35% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹289.72 Cr ▲ 1.35%
Profit · FY 2026
-₹3.31 Cr ▼ 146.57%
EBITDA · FY 2026
-₹1.31 Cr ▼ 111.64%
Revenue₹ Cr · Standalone0200400FY 2019: ₹111 Cr111FY 2019FY 2020: ₹137 Cr · +23.7% YoY137+23.7%FY 2020FY 2021: ₹179 Cr · +30.2% YoY179+30.2%FY 2021FY 2022: ₹222 Cr · +23.9% YoY222+23.9%FY 2022FY 2023: ₹311 Cr · +40% YoY311+40%FY 2023FY 2024: ₹282 Cr · -9.4% YoY282-9.4%FY 2024FY 2025: ₹286 Cr · +1.5% YoY286+1.5%FY 2025FY 2026: ₹290 Cr · +1.4% YoY290+1.4%FY 2026
Net Profit₹ Cr · Standalone-1001020FY 2019: ₹2 Cr1.5FY 2019FY 2020: ₹4 Cr · +175.9% YoY4.2+175.9%FY 2020FY 2021: ₹5 Cr · +25.9% YoY5.3+25.9%FY 2021FY 2022: ₹17 Cr · +222.2% YoY17.2+222.2%FY 2022FY 2023: ₹17 Cr · -3.2% YoY16.6-3.2%FY 2023FY 2024: ₹2 Cr · -87% YoY2.2-87%FY 2024FY 2025: ₹7 Cr · +228.9% YoY7.1+228.9%FY 2025FY 2026: ₹3 Cr (loss) · -146.6% YoY-3.3FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year050100Q1'25: ₹81 Cr80.8Q1'25Q2'25: ₹70 Cr70.2Q2'25Q3'25: ₹64 Cr63.7Q3'25Q4'25: ₹71 Cr71.2Q4'25Q1'26: ₹76 Cr · -6.4% YoY75.7-6.4%Q1'26Q2'26: ₹79 Cr · +12.4% YoY78.9+12.4%Q2'26Q3'26: ₹63 Cr · -0.4% YoY63.4-0.4%Q3'26Q4'26: ₹72 Cr · +0.8% YoY71.8+0.8%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹289.72 Cr ₹285.86 Cr ₹281.58 Cr ₹310.65 Cr ₹221.81 Cr ₹179.02 Cr ₹137.45 Cr ₹111.14 Cr
Other Income ₹83.37 Lakh ₹97.34 Lakh ₹1.38 Cr ₹47.77 Lakh ₹55.08 Lakh ₹46.28 Lakh ₹57.22 Lakh ₹45.67 Lakh
Total Income ₹290.55 Cr ₹286.83 Cr ₹282.97 Cr ₹311.12 Cr ₹222.36 Cr ₹179.48 Cr ₹138.02 Cr ₹111.59 Cr
Cost of Materials Consumed ₹289.67 Cr ₹269.27 Cr ₹265.48 Cr ₹288 Cr ₹190.23 Cr ₹162.02 Cr ₹131.8 Cr ₹103.53 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹6.62 Cr -₹2.52 Cr ₹4.84 Cr -₹10.14 Cr -₹33.33 Lakh ₹2.23 Cr -₹6.18 Cr -₹90.93 Lakh
Employee Benefit Expense ₹2.28 Cr ₹2.22 Cr ₹2.22 Cr ₹1.88 Cr ₹1.77 Cr ₹1.5 Cr ₹1.44 Cr ₹1.38 Cr
Finance Costs ₹95.53 Lakh ₹67.41 Lakh ₹68.7 Lakh ₹1.23 Cr ₹67.45 Lakh ₹1.28 Cr ₹97.83 Lakh ₹1.06 Cr
Depreciation & Amortisation ₹71.98 Lakh ₹65.47 Lakh ₹64.69 Lakh ₹64.3 Lakh ₹59.47 Lakh ₹49.29 Lakh ₹42.63 Lakh ₹41.77 Lakh
Other Expenses ₹6.54 Cr ₹6.65 Cr ₹6.58 Cr ₹6.97 Cr ₹5.79 Cr ₹4.61 Cr ₹3.76 Cr ₹3.95 Cr
Total Expenses ₹293.54 Cr ₹276.95 Cr ₹280.45 Cr ₹288.59 Cr ₹198.74 Cr ₹172.12 Cr ₹132.23 Cr ₹109.44 Cr
Profit Before Exceptional Items & Tax -₹2.98 Cr ₹9.89 Cr ₹2.52 Cr ₹22.53 Cr ₹23.62 Cr ₹7.36 Cr ₹5.8 Cr ₹2.16 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 -₹2.34 Lakh -₹1.77 Lakh -₹1.2 Lakh ₹0
Profit Before Tax -₹2.98 Cr ₹9.89 Cr ₹2.52 Cr ₹22.53 Cr ₹23.6 Cr ₹7.34 Cr ₹5.79 Cr ₹2.16 Cr
Total Tax Expense ₹33.1 Lakh ₹2.77 Cr ₹35.76 Lakh ₹5.9 Cr ₹6.42 Cr ₹2.01 Cr ₹1.55 Cr ₹62.21 Lakh
Net Profit -₹3.31 Cr ₹7.11 Cr ₹2.16 Cr ₹16.63 Cr ₹17.18 Cr ₹5.33 Cr ₹4.24 Cr ₹1.54 Cr
Other Comprehensive Income ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income -₹3.31 Cr ₹7.11 Cr ₹2.16 Cr ₹16.63 Cr ₹17.18 Cr ₹5.33 Cr ₹4.24 Cr ₹1.54 Cr
EBITDA (computed) -₹1.31 Cr ₹11.21 Cr ₹3.85 Cr ₹24.41 Cr ₹24.89 Cr ₹9.13 Cr ₹7.2 Cr ₹3.63 Cr
Basic EPS ₹-10.72 ₹23.02 ₹7.00 ₹53.83 ₹55.62 ₹17.26 ₹13.71 ₹4.97
Diluted EPS ₹-10.72 ₹23.02 ₹7.00 ₹53.83 ₹55.62 ₹17.26 ₹13.71 ₹4.97
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹124.42 Cr ₹121.49 Cr ₹121.74 Cr ₹116.15 Cr ₹84.61 Cr ₹57.4 Cr ₹58.35 Cr ₹40.23 Cr
Non-current Assets ₹20.63 Cr ₹18.13 Cr ₹19.17 Cr ₹17.54 Cr ₹10.79 Cr ₹10.07 Cr ₹8.67 Cr ₹7.47 Cr
Current Assets ₹103.79 Cr ₹103.36 Cr ₹102.57 Cr ₹98.62 Cr ₹73.82 Cr ₹47.32 Cr ₹49.68 Cr ₹32.76 Cr
Property, Plant & Equipment ₹11.7 Cr ₹10.47 Cr ₹10.72 Cr ₹10.7 Cr ₹9.98 Cr ₹9.39 Cr ₹7.18 Cr ₹6.84 Cr
Inventories ₹43.62 Cr ₹38.01 Cr ₹20.68 Cr ₹32.53 Cr ₹12.42 Cr ₹11.4 Cr ₹18.77 Cr ₹7.93 Cr
Trade Receivables ₹51.05 Cr ₹56.54 Cr ₹69.28 Cr ₹51.24 Cr ₹43.57 Cr ₹33.01 Cr ₹27.81 Cr ₹21.05 Cr
Cash & Equivalents ₹5.88 Cr ₹4.83 Lakh ₹9.67 Cr ₹11.86 Cr ₹17.27 Cr ₹2.54 Cr ₹1.17 Cr ₹2.25 Cr
Equity (Net Worth) ₹68.18 Cr ₹71.8 Cr ₹65 Cr ₹63.14 Cr ₹46.82 Cr ₹29.64 Cr ₹24.3 Cr ₹20.07 Cr
Equity Share Capital ₹3.09 Cr ₹3.09 Cr ₹3.09 Cr ₹3.09 Cr ₹3.09 Cr ₹3.09 Cr ₹3.09 Cr ₹3.09 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹31.28 Lakh
Borrowings (Current) ₹10.71 Cr ₹9.91 Cr ₹8.45 Cr ₹18.66 Cr ₹7.52 Cr ₹8.79 Cr ₹9.1 Cr ₹5.77 Cr
Total Debt (computed) ₹10.71 Cr ₹9.91 Cr ₹8.45 Cr ₹18.66 Cr ₹7.52 Cr ₹8.79 Cr ₹9.1 Cr ₹6.08 Cr
Current Liabilities ₹55.82 Cr ₹49.58 Cr ₹56.4 Cr ₹52.75 Cr ₹37.33 Cr ₹27.33 Cr ₹33.9 Cr ₹19.33 Cr
Total Liabilities ₹56.24 Cr ₹49.69 Cr ₹56.74 Cr ₹53.01 Cr ₹37.79 Cr ₹27.76 Cr ₹34.04 Cr ₹20.16 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹8.88 Cr -₹10.09 Cr ₹9.41 Cr -₹9.44 Cr ₹17.78 Cr
Investing Cash Flow -₹2.57 Cr -₹49,000 -₹40.6 Lakh -₹3.01 Cr -₹1.37 Cr
Financing Cash Flow -₹47.19 Lakh ₹47.71 Lakh -₹11.2 Cr ₹9.6 Cr -₹1.95 Cr
Capital Expenditure ₹3.08 Cr ₹41.2 Lakh ₹66.67 Lakh ₹1.36 Cr ₹1.28 Cr
Free Cash Flow (computed) ₹5.8 Cr -₹10.5 Cr ₹8.75 Cr -₹10.8 Cr ₹16.51 Cr
Dividends Paid ₹30.9 Lakh ₹30.9 Lakh ₹30.9 Lakh ₹30.9 Lakh ₹0
Net Change in Cash ₹5.83 Cr -₹9.62 Cr -₹2.19 Cr -₹2.84 Cr ₹14.46 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹71.77 Cr ₹63.43 Cr ₹78.87 Cr ₹75.65 Cr ₹71.2 Cr ₹63.66 Cr ₹70.17 Cr ₹80.82 Cr
Other Income -₹30.67 Lakh ₹40.1 Lakh ₹4.81 Lakh ₹69.13 Lakh -₹10.73 Lakh ₹41,000 ₹49.07 Lakh ₹58.59 Lakh
Total Income ₹71.47 Cr ₹63.83 Cr ₹78.92 Cr ₹76.34 Cr ₹71.1 Cr ₹63.67 Cr ₹70.66 Cr ₹81.41 Cr
Cost of Materials Consumed ₹70.38 Cr ₹63.44 Cr ₹73.33 Cr ₹82.52 Cr ₹62.63 Cr ₹64.72 Cr ₹63.77 Cr ₹78.16 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹34.61 Lakh -₹1.65 Cr ₹3.81 Cr -₹9.13 Cr ₹6.16 Cr -₹7.71 Cr ₹80.98 Lakh -₹1.78 Cr
Employee Benefit Expense ₹68.8 Lakh ₹53.33 Lakh ₹54.69 Lakh ₹50.78 Lakh ₹65.57 Lakh ₹56.25 Lakh ₹50.27 Lakh ₹50 Lakh
Finance Costs ₹13.65 Lakh ₹12.56 Lakh ₹25.53 Lakh ₹43.79 Lakh ₹22.16 Lakh ₹9.63 Lakh ₹16.5 Lakh ₹19.12 Lakh
Depreciation & Amortisation ₹18.55 Lakh ₹18.58 Lakh ₹17.85 Lakh ₹17 Lakh ₹16.04 Lakh ₹16.65 Lakh ₹16.69 Lakh ₹16.09 Lakh
Other Expenses ₹1.6 Cr ₹1.77 Cr ₹1.54 Cr ₹1.63 Cr ₹1.64 Cr ₹1.92 Cr ₹1.73 Cr ₹1.36 Cr
Total Expenses ₹73.34 Cr ₹64.39 Cr ₹79.67 Cr ₹76.14 Cr ₹71.46 Cr ₹59.75 Cr ₹67.14 Cr ₹78.59 Cr
Profit Before Exceptional Items & Tax -₹1.87 Cr -₹56.71 Lakh -₹74.84 Lakh ₹20.78 Lakh -₹36.35 Lakh ₹3.91 Cr ₹3.52 Cr ₹2.82 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹1.87 Cr -₹56.71 Lakh -₹74.84 Lakh ₹20.78 Lakh -₹36.35 Lakh ₹3.91 Cr ₹3.52 Cr ₹2.82 Cr
Total Tax Expense ₹16.3 Lakh -₹10.76 Lakh -₹16.11 Lakh ₹43.67 Lakh ₹3.57 Lakh ₹1.13 Cr ₹85.74 Lakh ₹75.3 Lakh
Net Profit -₹2.04 Cr -₹45.95 Lakh -₹58.73 Lakh -₹22.89 Lakh -₹39.92 Lakh ₹2.78 Cr ₹2.66 Cr ₹2.07 Cr
Other Comprehensive Income ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income -₹2.04 Cr -₹45.95 Lakh -₹58.73 Lakh -₹22.89 Lakh -₹39.92 Lakh ₹2.78 Cr ₹2.66 Cr ₹2.07 Cr
EBITDA (computed) -₹1.55 Cr -₹25.57 Lakh -₹31.46 Lakh ₹81.57 Lakh ₹1.85 Lakh ₹4.18 Cr ₹3.85 Cr ₹3.17 Cr
Basic EPS ₹-6.59 ₹-1.49 ₹-1.90 ₹-0.74 ₹-1.29 ₹9.01 ₹8.61 ₹6.68
Diluted EPS ₹-6.59 ₹-1.49 ₹-1.90 ₹-0.74 ₹-1.29 ₹9.01 ₹8.61 ₹6.68
Latest 8 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Samrat Pharmachem Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Samrat Pharmachem Limited

As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 49.09%, foreign institutional investors hold 3.24%, retail and other public shareholders hold 47.67% of Samrat Pharmachem Limited. The company had 6,311 shareholders on record.

Promoters: 49.09%FII (Foreign Institutional): 3.24%Retail & Others: 47.67%
Mar 2026
QUARTER
49.09% Promoters
3.24% FII (Foreign Institutional)
47.67% Retail & Others
Promoter holding - history
Now 49.09% · Mar 2026High 49.09% · Dec 2024Low 48.64% · Jun 2023
47%48%49%50%51%Jun 2023Dec 2023Jun 2024Dec 2024Jun 2025Dec 2025Jun 2023: 48.64%Sep 2023: 48.64%Dec 2023: 48.64%Mar 2024: 48.64%Jun 2024: 48.64%Sep 2024: 48.95%Dec 2024: 49.09%Mar 2025: 49.09%Jun 2025: 49.09%Sep 2025: 49.09%Dec 2025: 49.09%Mar 2026: 49.09%49.09%48.64%49.09%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters49.09%49.09%49.09%49.09%49.09%49.09%
Public50.91%50.91%50.91%50.91%50.91%50.91%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024
Promoters49.09%49.09%48.64%
Public50.91%50.91%51.36%
Promoter change (YoY, %pts)+0.00+0.45-

Charges & Borrowings of Samrat Pharmachem Limited

Open charges
₹69 Cr
Satisfied charges
₹17.55 Cr
Breakdown by lending institutions
Others₹67.00 Cr
Icici Bank Limited₹2.00 Cr
Latest charge details
DateLenderAmountStatus
05 Dec 2011 Others ₹2 Cr Open
21 Oct 2011 Icici Bank Limited ₹2 Cr Open
22 Dec 2007 Others ₹48 Cr Open
02 Nov 2005 Others ₹17 Cr Open
19 Oct 2011 Hdfc Bank Limited ₹3.2 Cr Satisfied

Total charge records: 9 View all charges

Employees and EPFO Compliance at Samrat Pharmachem Limited

Samrat Pharmachem Limited has a workforce of 26 employees as of Aug 19, 2025.

Employee count
26
Active EPFO establishments
1
Employee growth
-7.14%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Samrat Pharmachem Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Samrat Pharmachem Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Samrat Pharmachem Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Samrat Pharmachem Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Samrat Pharmachem Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Samrat Pharmachem Limited

MSME Payment Delays by Samrat Pharmachem Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Samrat Pharmachem Limited

Subsidiaries & Group Companies of Samrat Pharmachem Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Samrat Pharmachem Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Samrat Pharmachem Limited

MCA Filings & Documents of Samrat Pharmachem Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Samrat Pharmachem Limited

Activity
25 Sep 2025
Samrat Pharmachem Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Directors
16 Jul 2025
Piyush Gangji Dharod was appointed as a Director on 16 Jul 2025 & has been associated with this company since 11 months 23 days.
Charges
10 Jul 2025
A charge with Others of Rs. 48.00 Cr registered on 22 Dec 2007 with Charge ID 10101754 was modified on 10 Jul 2025.
Activity
31 Mar 2025
Samrat Pharmachem Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad.
Directors
01 Aug 2024
Megha Sanjay Jain was appointed as a Additional Director on 01 Aug 2024 & has been associated with this company since 1 year 11 months.
Directors
23 Jul 2024
Manishkumar Indukumar Pipalia was appointed as a Director on 23 Jul 2024 & has been associated with this company since 1 year 11 months.

Frequently Asked Questions about Samrat Pharmachem Limited

Samrat Pharmachem Limited is an active public limited company in the chemicals and materials sector based in Ankleshwar, Gujarat, India. It was incorporated on 16 June 1992 (34+ years old) and is registered under CIN L24230GJ1992PLC017820. Listed on BSE: 530125. The company has 26 employees.

Samrat Pharmachem Limited reported revenue of ₹286.83 Cr for FY 2025 (up 1.00% YoY).

The current directors of Samrat Pharmachem Limited are:

The primary industry of Samrat Pharmachem Limited is chemicals and materials. The company specifically operates in specialty chemicals. The company is currently active in this sector.

Yes. Samrat Pharmachem Limited is listed on BSE with code 530125.

Samrat Pharmachem Limited can be reached at the registered office: Plot No. A2 – 3444 – 3445, Gidc Phase 4, Ankleshwar, Gujarat, India – 393002, or through the website samratpharmachem.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available